Cambridge, MA-based TransMolecular, a developer of cancer drugs based on a molecule derived from scorpion venom, said today it has named Robert Radie as its president and CEO. Before joining TransMolecular as a business development consultant, Radie held leadership roles at Prestwick Pharmaceuticals, Morphotek, and Vicuron Pharmaceuticals.
Sponsored · Whitepaper
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace
Sponsored · Webinar
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX
From Our Editors · Podcast
The AI, Big Data, and R&D Boom
